Member access

4-Traders Homepage  >  Shares  >  Nasdaq  >  Sucampo Pharmaceuticals, Inc.    SCMP   US8649091068

 SummaryQuotesChart AnalysisNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq
01/21/2015 01/22/2015 01/23/2015 01/26/2015 01/27/2015 Date
15.07(c) 15.43(c) 15.18(c) 15.99(c) 15.97(c) Last
467 414 195 909 115 641 498 508 320 645 Volume
-3.77% +2.39% -1.62% +5.34% -0.13% Change
More quotes
Company
Sucampo Pharmaceuticals, Inc. is a biopharmaceutical company which engages in research, discovery, development and commercialization of proprietary drugs based on prostones and other novel drug technologies.Prostones are naturally occurring fatty acid metabolites with unique physiological... 
Sector
Biotechnology & Medical Research
Calendar
02/10 | 01:30pmPresentation
More about the company
Surperformance© ratings of Sucampo Pharmaceuticals, I
Trading Rating : Investor Rating :
More Ratings
Chart SUCAMPO PHARMACEUTICALS, I
Duration : Period :
Sucampo Pharmaceuticals, I Technical Analysis Chart | SCMP | US8649091068 | 4-Traders
Full-screen chart
Financials ($)
Sales 2014 119 M
EBIT 2014 31,7 M
Net income 2014 10,9 M
Finance 2014 16,5 M
Yield 2014 -
Sales 2015 130 M
EBIT 2015 42,0 M
Net income 2015 23,9 M
Finance 2015 54,6 M
Yield 2015 -
PER 2014 75,15
PER 2015 29,85
EV / Sales 2014 5,80x
EV / Sales 2015 5,03x
Capitalization 708 M
More Financials
Latest news on SUCAMPO PHARMACEUTICALS, I
01/21 Robert J. Spiegel, M.D., FACP Joins Sucampo's Board of Directors
01/12 SUCAMPO PHARMACEUTICALS : Regulation FD Disclosure, Financial Statements and Exh..
2014 SUCAMPO PHARMACEUTICALS : Daily Pharma Dose: New Research on Hospira, Aquinox, S..
2014 Sucampo Announces Acceptance of New Drug Submission for AMITIZA(R) (lubiprost..
2014 Sucampo Appoints John H. Johnson to Board of Directors
2014 SUCAMPO PHARMACEUTICALS : Announces Webcast of Its Presentation at the 26th Annu..
2014 SUCAMPO PHARMACEUTICALS : Files Patent Infringement Lawsuit Against Dr. Reddy's
2014 SUCAMPO PHARMACEUTICALS : Regulation FD Disclosure (form 8-K)
More news
Sector news Bio Therapeutic Drugs
01/27 QIAGEN NV : Introduces QuantiFERON Monitor® for Tracking Immune Function in Soli..
01/27 PUMA BIOTECHNOLOGY : Closes $218 Million Public Offering of Common Stock
01/27 INCYTE : to Report Fourth Quarter/Year-End 2014 Financial Results on February 12
Plus d'actualités du secteur Bio Therapeutic Drugs


Comments 
Advertisement
Technical analysis trends
Short TermMid-TermLong Term
TrendsBullishBullishBullish
Technical analysis
Income Statement Evolution
More Financials
EPS Revisions
More Estimates Revisions
Dynamic quotes  
ON
| OFF